Friedlaender, Alex, et al. “Impact of Performance Status on Non-Small-Cell Lung Cancer Patients With a PD-L1 Tumour Proportion Score ≥50% Treated With Front-Line Pembrolizumab”. Acta Oncologica, vol. 59, no. 9, Sept. 2020, pp. 1058-63, doi:10.1080/0284186X.2020.1781249.